TheProfitWatch

LRMR - Larimar Therapeutics, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
3.2 0.33 (10.31%) --- -0.01 (-0.28%) -0.03 (-0.7%) 0.29 (9.06%) 0.19 (5.69%) --- 0.29 (9.06%)

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Category: PHARMACEUTICAL PREPARATIONS
Market Period: Market

Earnings & Ratios

Basic EPS:
-0.41
Diluted EPS:
-0.41
Basic P/E:
-8.6098
Diluted P/E:
-8.6098
RSI(14) 1m:
37.5
VWAP:
3.53
RVol:

Events

Period Kind Movement Occurred At

Related News